Antigens onto bare skin: a ‘painless’ paradigm shift in vaccine delivery

Partidos, Charalambos D.

doi:10.1517/14712598.3.6.895

Cited by 8 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…group. These results confirm previous reports about the safety of both of these modes of administration (4,6,7,26). We further demonstrated that MVA vaccination by t.c.…”

Section: Discussionsupporting

confidence: 92%

Presentation_1.pptx

View full text Add to dashboard Cite

“…group. These results confirm previous reports about the safety of both of these modes of administration (4,6,7,26). We further demonstrated that MVA vaccination by t.c.…”

Section: Discussionsupporting

confidence: 92%

“…The approaches described to date have focussed on the delivery of PA to the mucosal surfaces of the gut and upper respiratory tract. The development of transcutaneous delivery systems capable of delivering therapeutic agents has enabled researchers to apply vaccines directly to external skin surfaces (Partidos 2003). The effectiveness of this approach as a means of stimulating a protective immune response against anthrax has been recently demonstrated in mice (Kenney et al.…”

Section: Medical Countermeasuresmentioning

confidence: 99%

Past, imminent and future human medical countermeasures for anthrax

Baillie

2006

J Appl Microbiol

View full text Add to dashboard Cite

Aim: Anthrax is caused by the bacterium Bacillus anthracis. Although primarily a disease of animals, it can also infect man, sometimes with fatal consequences. As a result of concerns over the illicit use of this organism, considerable effort is focussed on the development of therapies capable of conferring protection against anthrax. This brief review will describe the efforts being made to address these issues. Methods and Results: A review of the literature and the proceedings of the sixth international conference on anthrax, held in Santa Fe, USA in 2005 shows intense activity, but there has been as yet no real progress. While effective antibiotics, antitoxins and vaccines are available, concerns over their toxicity and the emergence of resistant strains have driven the development of second‐generation products. The principal target for vaccine development is Protective Antigen (PA), the nontoxic cell‐binding component of anthrax lethal toxin. While the recombinant products currently undergoing human clinical trials will offer considerable advantages in terms of reduced side effects and ease of production, they would still require multiple, needle‐based dosing, and the inclusion of the adjuvant alum makes them expensive to administer and stockpile. To address these issues, researchers are developing vaccine formulations, which stimulate rapid protection following needle‐free injection (nasal, oral or transcutaneous), and are stable at room temperature to facilitate stockpiling and mass vaccination programs. Conclusions: An array of medical countermeasures targeting B. anthracis will become available over the next 5–10 years. Significance and Impact of the Study: The huge investment of research dollars is expected to dramatically expand the knowledge base. A better understanding of basic issues, such as survival in nature and pathogenesis in humans, will facilitate the development of new modalities to eliminate the threat posed by this organism.

show abstract